← Leaderboards
Richard W Foltin
Columbia University Health Sciences
$21,307,956
Attributed
$25,514,307
Total exposure
28
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$25,514,307 · 28
By mechanism
R01$20,880,040 · 10
M01$2,890,151 · 13
K05$641,035 · 1
R03$455,760 · 2
R21$418,694 · 1
P50$228,627 · 1
Top collaborators
- Suzette M Evans6 shared
- Yuanjia Wang5 shared
- Diana M Martinez2 shared
- Michael Charles Salling2 shared
- Stanislav R Vorel2 shared
- Ziva D Cooper1 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Judith Korner$12,592,020
- Steven M Kawut$28,347,465
- Andrea Califano$71,130,512
Others in their field
Top investigators on “Cocaine”
- Sten H Vermund · University Of Alabama At Birmingham$115,253,143
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$42,690,128
- Joel Gelernter · Washington University$34,364,949
- Michael A Nader · Emory University$33,226,167
- Shenghan Lai · University Of Miami Coral Gables$31,568,530
Research focus
CocainePharmaceutical PreparationsClinical ResearchDrug AbuseBehaviorBaseResponseHuman SubjectBehavioralReinforcerNonhuman PrimateFoodDrug UsageFemaleProceduresSmokeSelf-AdministeredSelf AdministrationAmphetaminesAffectMaleBrainMotivationEating
Grant awards (91)
Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin$620,238
R01 · FY2022 · DA
Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin$620,927
R01 · FY2021 · DA
Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin$579,018
R01 · FY2020 · DA
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome$625,447
R01 · FY2018 · DA · contact PI
Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin$592,695
R01 · FY2018 · DA
Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin$680,047
R01 · FY2017 · DA
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome$625,447
R01 · FY2017 · DA · contact PI
A Pilot Study of Deep Brain Stimulation for Alcohol Dependence$181,815
R21 · FY2017 · AA
Automated Speech Analysis: A Marker of Drug Intoxication & Treatment Outcome$81,000
R03 · FY2017 · DA · contact PI
Preclinical Synthetic Cannabinoid Vapor Inhalation: Acute and Chronic Effects$717,669
R01 · FY2016 · DA
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome$592,417
R01 · FY2016 · DA · contact PI
A Pilot Study of Deep Brain Stimulation for Alcohol Dependence$236,879
R21 · FY2016 · AA
Preclinical Synthetic Cannabinoid Vapor Inhalation: Acute and Chronic Effects$708,676
R01 · FY2015 · DA
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome$589,426
R01 · FY2015 · DA · contact PI
Clinical and Preclinical Models in Drug Abuse: Training and Development$128,207
K05 · FY2015 · DA · contact PI
Impulsivity In Cocaine Abusers: Relationship to Drug Taking and Treatment Outcome$527,676
R01 · FY2014 · DA · contact PI
Hypocretin Antagonists as a Novel Approach to Medication Development$375,640
R01 · FY2014 · DA · contact PI
Clinical and Preclinical Models in Drug Abuse: Training and Development$128,207
K05 · FY2014 · DA · contact PI
Hypocretin Antagonists as a Novel Approach to Medication Development$367,153
R01 · FY2013 · DA · contact PI
Clinical and Preclinical Models in Drug Abuse: Training and Development$128,207
K05 · FY2013 · DA · contact PI
Hypocretin Antagonists as a Novel Approach to Medication Development$388,628
R01 · FY2012 · DA · contact PI
Clinical and Preclinical Models in Drug Abuse: Training and Development$128,207
K05 · FY2012 · DA · contact PI
Translational Approach to Models in Relapse$543,293
R01 · FY2011 · DA · contact PI
Hypocretin Antagonists as a Novel Approach to Medication Development$411,927
R01 · FY2011 · DA · contact PI
Anorectic Drugs: Abuse and Behavioral Mechanisms of Action$220,529
R01 · FY2011 · DA · contact PI
Clinical and Preclinical Models in Drug Abuse: Training and Development$128,207
K05 · FY2011 · DA · contact PI
Translational Approach to Models in Relapse$547,424
R01 · FY2010 · DA · contact PI
Anorectic Drugs: Abuse and Behavioral Mechanisms of Action$224,965
R01 · FY2010 · DA · contact PI
NMDA Glutamate Receptor Transmission in Extinction of Cocaine-Seeking Behavior$187,814
R03 · FY2010 · DA
Translational Approach to Models in Relapse$540,137
R01 · FY2009 · DA · contact PI
Anorectic Drugs: Abuse and Behavioral Mechanisms of Action$290,611
R01 · FY2009 · DA · contact PI
NMDA Glutamate Receptor Transmission in Extinction of Cocaine-Seeking Behavior$186,946
R03 · FY2009 · DA
Anorectic Drugs: Abuse and Behavioral Mechanisms of Action$264,068
R01 · FY2008 · DA · contact PI
IV COCAINE ABUSE TREATMENT: A LABORATORY MODEL$591,862
R01 · FY2007 · DA · contact PI
Translational Approach to Models in Relapse$554,653
R01 · FY2007 · DA · contact PI
Laboratory Analysis of Cocaine Abstinence$462,584
R01 · FY2007 · DA · contact PI
Anorectic Drugs: Abuse and Behavioral Mechanisms of Action$292,187
R01 · FY2007 · DA · contact PI
Laboratory Analysis of Cocaine Abstinence$469,053
R01 · FY2006 · DA · contact PI
IV COCAINE ABUSE TREATMENT: A LABORATORY MODEL$606,027
R01 · FY2005 · DA
Laboratory Analysis of Cocaine Abstinence$456,763
R01 · FY2005 · DA
COCAINE EFFECTS IN HUMANS: PHYSIOLOGY AND BEHAVIOR$406,438
M01 · FY2005 · RR
TREATMENT OF COCAINE ABUSE IN INDIVIDUALS WITH COMORBID DISORDERS$251,605
M01 · FY2005 · RR
GABAPENTIN FOR COCAINE ABUSE$101,932
M01 · FY2005 · RR
MODAFINIL AS POTENTIAL PHARMACOTHERAPY FOR COCAINE ABUSE$77,417
M01 · FY2005 · RR
LABORATORY MODEL FOR ASSESSING CHANGES IN THE MOTIVATION TO SMOKE COCAINE$69,030
M01 · FY2005 · RR
MODULATION OF PROGESTERONE$50,966
M01 · FY2005 · RR
INTRANASAL COCAINE$47,096
M01 · FY2005 · RR
ABUSE POTENTIAL$34,192
M01 · FY2005 · RR
IV COCAINE ABUSE TREATMENT: A LABORATORY MODEL$593,721
R01 · FY2004 · DA
Laboratory Analysis of Cocaine Abstinence$440,271
R01 · FY2004 · DA
Cocaine Effects in Humans: Physiology and Behavior$257,443
M01 · FY2004 · RR
ANORECTIC DRUGS: ABUSE &BEHAVIORAL MECHANISMS OF ACTION$175,750
R01 · FY2004 · DA
Modulation of Progesterone$121,640
M01 · FY2004 · RR
Gabapentin for Cocaine Abuse$112,198
M01 · FY2004 · RR
Modafinil as Potential Pharmacotherapy for Cocaine Abuse$79,149
M01 · FY2004 · RR
Abuse Potential$58,876
M01 · FY2004 · RR
Treatment of Cocaine Abuse in Individuals with Comorbid Disorders$34,159
M01 · FY2004 · RR
Intranasal Cocaine$16,386
M01 · FY2004 · RR
Laboratory Model For Assessing Changes in the Motivation to Smoke Cocaine$14,164
M01 · FY2004 · RR
IV COCAINE ABUSE TREATMENT: A LABORATORY MODEL$579,586
R01 · FY2003 · DA
Laboratory Analysis of Cocaine Abstinence$432,005
R01 · FY2003 · DA
ANORECTIC DRUGS: ABUSE &BEHAVIORAL MECHANISMS OF ACTION$175,750
R01 · FY2003 · DA
Laboratory Analysis of Cocaine Abstinence$38,864
R01 · FY2003 · DA
IV COCAINE ABUSE TREATMENT: A LABORATORY MODEL$567,564
R01 · FY2002 · DA
LABORATORY ANALYSIS OF COCAINE ABSTINENCE$410,590
R01 · FY2002 · DA
LABORATORY STUDIES OF COCAINE ABSTINENCE--CONDITIONING$192,910
M01 · FY2002 · RR
INTRANASAL COCAINE IN MEN AND WOMEN$192,910
M01 · FY2002 · RR
BROMOCRIPTINE$192,910
M01 · FY2002 · RR
ANORECTIC DRUGS: ABUSE &BEHAVIORAL MECHANISMS OF ACTION$175,750
R01 · FY2002 · DA
Laboratory Studies of Novel Cocaine Pharmacotherapies$0
P50 · FY2002 · DA
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL$597,984
R01 · FY2001 · DA
LABORATORY ANALYSIS OF COCAINE ABSTINENCE$399,001
R01 · FY2001 · DA
BROMOCRIPTINE$192,910
M01 · FY2001 · RR
INTRANASAL COCAINE IN MEN AND WOMEN$192,910
M01 · FY2001 · RR
LABORATORY STUDIES OF COCAINE ABSTINENCE--CONDITIONING$192,910
M01 · FY2001 · RR
ANORECTIC DRUGS: ABUSE &BEHAVIORAL MECHANISMS OF ACTION$175,750
R01 · FY2001 · DA
BROMOCRIPTINE$0
M01 · FY2001 · RR
Laboratory Studies of Novel Cocaine Pharmacotherapies$0
P50 · FY2001 · DA
INTRANASAL COCAINE IN MEN AND WOMEN$0
M01 · FY2001 · RR
LABORATORY STUDIES OF COCAINE ABSTINENCE--CONDITIONING$0
M01 · FY2001 · RR
LABORATORY ANALYSIS OF COCAINE ABSTINENCE$387,749
R01 · FY2000 · DA
COCAINE'S EFFECTS ACROSS THE MENSTRUAL CYCLE$266,415
R01 · FY2000 · DA
Laboratory Studies of Novel Cocaine Pharmacotherapies$228,627
P50 · FY2000 · DA
NOVEL ANIMAL MODEL FOR TREATING COCAINE CRAVING$200,353
R01 · FY2000 · DA
ANORECTIC DRUGS: ABUSE &BEHAVIORAL MECHANISMS OF ACTION$175,750
R01 · FY2000 · DA
LABORATORY STUDIES OF COCAINE ABSTINENCE--CONDITIONING$0
M01 · FY2000 · RR
BROMOCRIPTINE$0
M01 · FY2000 · RR
INTRANASAL COCAINE IN MEN AND WOMEN$0
M01 · FY2000 · RR
INTRANASAL COCAINE IN MEN AND WOMEN$0
M01 · FY2000 · RR
LABORATORY STUDIES OF COCAINE ABSTINENCE--CONDITIONING$0
M01 · FY2000 · RR
BROMOCRIPTINE$0
M01 · FY2000 · RR